The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity

被引：4
|
作者：
Godwin, Colin D. [1 ,2 ]
Bates, Olivia M. [1 ]
Garling, Eliotte E. [1 ]
Beddoe, Mary E. [1 ]
Laszlo, George S. [1 ]
Walter, Roland B. [1 ,2 ,3 ,4 ]
机构：
[1] Univ Washington, Fred Hutchinson Canc Res Ctr, Clin Res Div, Seattle, WA 98195 USA
[2] Univ Washington, Dept Med, Div Hematol, Seattle, WA 98195 USA
[3] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[4] Univ Washington, Dept Pathol, Seattle, WA 98195 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2020年 / 189卷 / 01期
基金：
美国国家卫生研究院;
关键词：
acute leukaemia; bispecific antibody; Bruton's tyrosine kinase; ibrutinib; IL-2-inducible T-cell kinase;
D O I：
10.1111/bjh.16406
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E9 / +
页数：5
相关论文
共 50 条
  • [21] Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes
    Wei, Li
    Su, Yu-Kai
    Lin, Chien-Min
    Chao, Tsu-Yi
    Huang, Shang-Pen
    Thanh-Tuan Huynh
    Jan, Hsun-Jin
    Whang-Peng, Jacqueline
    Chiou, Jeng-Fong
    Wu, Alexander T. H.
    Hsiao, Michael
    ONCOTARGET, 2016, 7 (43) : 69961 - 69975
  • [22] T-cell expression of Bruton's tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia
    Xia, Simo
    Liu, Xiang
    Cao, Xuetao
    Xu, Sheng
    CELLULAR & MOLECULAR IMMUNOLOGY, 2020, 17 (10) : 1042 - 1052
  • [23] T-cell expression of Bruton’s tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia
    Simo Xia
    Xiang Liu
    Xuetao Cao
    Sheng Xu
    Cellular & Molecular Immunology, 2020, 17 : 1042 - 1052
  • [24] Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
    Sinha, Meenal
    Betts, Courtney
    Zhang, Li
    Griffith, Madeline J.
    Solman, Isabelle
    Chen, Brandon
    Liu, Eric
    Tamaki, Whitney
    Stultz, Jacob
    Marquez, Jaqueline
    Sivagnanam, Shamilene
    Cheung, Alexander
    Pener, Denise
    Fahlman, Anne
    Taber, Erin
    Lerner, Kimberly
    Crocker, Matthew
    Todd, Kendra
    Rajagopalan, Brindha
    Ware, Clarisha
    Bridge, Mark
    Vo, Johnson
    Dragomanovich, Hannah
    Sudduth-Klinger, Julie
    Vaccaro, Gina
    Lopez, Charles D.
    Tempero, Margaret
    Coussens, Lisa M.
    Fong, Lawrence
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (02)
  • [25] Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
    Sinha, Meenal
    Betts, Courtney
    Zhang, Li
    Griffith, Madeline J.
    Solman, Isabelle
    Chen, Brandon
    Liu, Eric
    Tamaki, Whitney
    Stultz, Jacob
    Marquez, Jaqueline
    Sivagnanam, Shamilene
    Cheung, Alexander
    Pener, Denise
    Fahlman, Anne
    Taber, Erin
    Lerner, Kimberly
    Crocker, Matthew
    Todd, Kendra
    Rajagopalan, Brindha
    Ware, Clarisha
    Bridge, Mark
    Vo, Johnson
    Dragomanovich, Hannah
    Sudduth-Klinger, Julie
    Vaccaro, Gina
    Lopez, Charles D.
    Tempero, Margaret
    Coussens, Lisa M.
    Fong, Lawrence
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (01)
  • [26] Ibrutinib (PCI-32765), the First BTK (Bruton’s Tyrosine Kinase) Inhibitor in Clinical Trials
    Jennifer R. Brown
    Current Hematologic Malignancy Reports, 2013, 8 : 1 - 6
  • [27] Effects of the Bruton's tyrosine kinase inhibitor ibrutinib on humoral immunity in patients with chronic lymphocytic leukemia
    Sun, Clare
    Lee, Yuh Shan
    Lipsky, Andrew
    Farooqui, Mohammed
    Herman, Sarah
    Salem, Dalia
    Stetler-Stevenson, Maryalice
    Yuan, Constance
    Aue, Georg
    Wiestner, Adrian
    JOURNAL OF IMMUNOLOGY, 2015, 194
  • [28] Ibrutinib (PCI-32765), the First BTK (Bruton's Tyrosine Kinase) Inhibitor in Clinical Trials
    Brown, Jennifer R.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2013, 8 (01) : 1 - 6
  • [29] Pretreatment with Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, Reduces Passive Systemic Anaphylaxis in a Murine Model
    Regan, Jennifer A.
    Krier-Burris, Rebecca
    O'Sullivan, Jeremy
    Bryce, Paul
    Bochner, Bruce S.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (02) : AB50 - AB50
  • [30] The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions
    Karel, M. F. A.
    Tullemans, B. M. E.
    D'Italia, G.
    Lemmens, T. P.
    Claushuis, T. A. M.
    Kuijpers, M. J. E.
    Cosemans, J. M. E. M.
    THROMBOSIS RESEARCH, 2022, 212 : 72 - 80
12345